Table 1 Incidence of experimentally validated aggregating peptides within the experimentally validated human T-cell autoimmune epitopes.

From: Autoimmune Responses to Soluble Aggregates of Amyloidogenic Proteins Involved in Neurodegenerative Diseases: Overlapping Aggregation Prone and Autoimmunogenic regions

  359 β-strand 158 amorphous β-aggregates 194 amyloid fibril 341 amyloid fibril 536 amyloid fibril
forming hexapeptides from globular proteins forming hexapeptides forming hexapeptides forming peptides of length 7–141 forming peptides of all lengths
155 HLA-DP binding 0 0 0 0 0
Autoimmune epitopes
543 HLA-DQ binding 0 31 (19.6%) 12 (6.2%) 13 (3.8%) 25 (4.7%)
Autoimmune epitopes
3243 HLA-DR binding 21 (5.8%) 18 (11.4%) 34 (17.5%) 150 (44%) 184 (34.3%)
Autoimmune epitopes
All 3941 T-cell 21 (5.8%) 49 (31%) 46 (23.7%) 163 (47.8%) 209 (39%)
autoimmune epitopes
430 MHCIInonbind 0 39 (24.7%) 7 (3.6%) 10 (2.9%) 17 (3.2%)
peptides
  1. Percentages were calculated with respect to the number of aggregating peptides in each column.